SCMOM 2012_RhinoCyte – Video

Posted: November 30, 2012 at 12:42 pm

SCMOM 2012_RhinoCyte
RhinoCyte trade;, Inc., is a biopharmaceutical company focused on developing innovative stem cell therapies for neurodegenerative diseases. Founded in 2005, the company has raised $5 million to date to develop this transformational technology to treat Spinal Cord Injury and Parkinson #39;s Disease to extend and enhance the quality of human life. The first RhinoCyte trade; product is for Spinal Cord Injury (SCI). The IND submission for SCI is 4Q12. RhinoCyte trade; is currently raising a $10 Million Series B financing to fund the Spinal Cord Injury Phase I Clinical Trial program and facilitate the clinical status of the Parkinson #39;s disease product. Presenter: Teresa Leezer, COO, RhinoCyteFrom:AllianceRegenMedViews:3 1ratingsTime:10:07More inScience Technology

Originally posted here:
SCMOM 2012_RhinoCyte - Video

Related Post

Comments are closed.